Budesonide + Formoterol

Budesonide is an inhaled corticosteroid that reduces inflammation in the airways, decreasing bronchial hyperresponsiveness and mucus production. Formoterol is a long-acting beta2-adrenergic agonist that acts locally in the lungs to relax bronchial smooth muscle, leading to rapid-onset and sustained bronchodilation. The combination synergistically provides both potent anti-inflammatory effects and sustained bronchodilation, effectively addressing the underlying pathology of asthma and COPD. Combination rationale: The combination of an inhaled corticosteroid (budesonide) and a long-acting beta2-agonist (formoterol) provides synergistic benefits for managing chronic respiratory conditions. Budesonide effectively reduces airway inflammation, while formoterol provides rapid and sustained bronchodilation. This FDC offers comprehensive control of both the inflammatory and bronchoconstrictive components of asthma and COPD, leading to improved lung function, symptom control, and reduced exacerbation rates compared to monotherapy.

Adult

Asthma: 1-2 inhalations of Budesonide/Formoterol (e.g., 100/6 mcg, 200/6 mcg, or 400/12 mcg) twice daily via dry powder inhaler (DPI) or metered-dose inhaler (MDI). Can also be used as a maintenance and reliever therapy (SMART regimen) where applicable. COPD: 2 inhalations of Budesonide/Formoterol (e.g., 200/6 mcg or 400/12 mcg) twice daily.

Pediatric

Asthma (6-11 years): 2 inhalations of Budesonide/Formoterol 80/4.5 mcg twice daily. Asthma (12 years and older): Same as adult dosing.

Renal adjustment

Not considered necessary for patients with renal impairment as systemic exposure of both components is minimal following inhalation and primarily cleared by hepatic metabolism.

Hepatic adjustment

Use with caution. Plasma clearance of budesonide is decreased in patients with hepatic impairment, potentially leading to increased systemic exposure. No specific dose adjustment guidelines for the combination, but monitor for increased corticosteroid-related adverse effects.

Geriatric

No specific dose adjustment is recommended for elderly patients, but monitor for increased susceptibility to cardiovascular side effects of formoterol.

Max dose

Clarify if the database's maximum dose includes "maintenance and reliever therapy (SMART)" regimens or other high-dose indications not covered by Harriet Lane's maintenance-only guidelines, and specify the relevant regions/guidelines for these higher doses.

• Primary treatment of status asthmaticus or other acute episodes of asthma or COPD requiring intensive measures.
• Hypersensitivity to budesonide, formoterol, or any excipients.
• Not for the relief of acute bronchospasm.